Glumetza Antitrust Case Sees More Settlements Ahead of Trial

Assertio Therapeutics Inc. and Lupin Ltd. have settled many of the antitrust claims they face over the blockbuster diabetes drug Glumetza, less than a week after Bausch Health Cos. agreed to a $300 million deal, according to federal court filings in San Francisco.

The drug distributors leading part of the case disclosed an agreement in principle with Assertio in a notice filed Tuesday, the same day the magistrate judge overseeing a settlement conference indicated in a brief docket entry that it had culminated in a tentative deal with Lupin.

Several large retailer pharmacies bringing related lawsuits, meanwhile, voluntarily dropped their ...